, Volume 68, Issue 2, pp 125–134 | Cite as

The comparison of the effects of DL-308, a potential new neuroleptic agent, and thioridazine on some psychological and physiological functions in healthy volunteers

  • E. Szabadi
  • C. M. Bradshaw
  • P. Gaszner
Original Investigations


Eight healthy male volunteers participated in four experimental sessions in which they ingested either DL-308 (10 mg), DL-308 (20 mg), thioridazine (50 mg) or placebo.. Drugs were allocated to subjects and sessions in a double-blind fashion according to a balanced cross-over design. Both DL-308 and thioridazine displayed sedative properties, as indicated by the sedated appearance of the subjects, by a decrease in subjectively rated alertness and by an impairment of performance on psychomotor tests. DL-308 appeared to be a more potent sedative than thioridazine. DL-308 (10 mg) caused an increase in subjectively rated sweating and objectively measured heart rate, suggesting a sympathomimetic property for the drug. DL-308, similarly to thioridazine, had effects consistent with an α-adrenolytic action; both drugs caused miosis, hypotension and a decrease in salivation. The decrease in salivation may also be consistent with an anticholinergic effect. When equisedative doses of the two drugs were compared, DL-308 had a much smaller influence on autonomic functions than thioridazine. DL-308 had a faster time-course of action than thioridazine. Peak effects were attained 1–3 h post-drug and the effects almost completely dissipated within 5 h. DL-308, similarly to thioridazine, had little effect on the motor system, as indicated by conventional clinical neurological examination.

Key words

DL-308 Thioridazine Healthy volunteers Psychomotor tests Autonomic functions Motor functions 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. Aitken, R. C. B.: Measurement of feelings using visual analogue scales. Proc. R. Soc. Med. 62, 989–993 (1969)Google Scholar
  2. Aitken, R. C. B., Zealley, A. K.: Measurement of moods. Br. J. Hosp. Med. 4, 215–224 (1970)Google Scholar
  3. Bickerstaff, E. R.: Neurological examination in clinical practice. Oxford: Blackwell 1973Google Scholar
  4. Bond, A. J., Lader, M. H.: The use of analog scales in rating subjective feelings. Br. J. Med. Psychol. 47, 211–218 (1974)Google Scholar
  5. Bürki, H. R.: Extrapyramidal side-effects. Pharmacol. Ther. 5, 524–534 (1979)Google Scholar
  6. Byck, R.: Drugs and the treatment of psychiatric disorders. In: The pharmacological basis of therapeutics, L. S. Goodman, A. Gilman, eds., pp. 152–200. New York: Macmillan 1975Google Scholar
  7. Hyttel, J.: Effect of neuroleptics on the disapearance rate of 14C-labelled catecholamines formed from 14C-tyrosine in mouse brain. J. Pharm. Pharmacol. 26, 588–596 (1974)Google Scholar
  8. Kornetsky, C., Humphries, O.: Psychological effects of centrally acting drugs in man: Effects of chlorpromazine and secobarbital on visual and motor behaviour. J. Ment. Sci. 104, 1093–1099 (1958)Google Scholar
  9. Kornetsky, C., Vates, T. S., Kessler, E. K.: A comparison of hypnotic and residual psychological effects of single doses of chlorpromazine and secobarbital in man. J. Pharmacol. Exp. Ther. 127, 51–54 (1959)Google Scholar
  10. Loga, S., Curry, S., Lader, M.: Interactions of orphanedrine and phenobarbitone with chlorpromazine: Plasma concentrations and effects in man. Br. J. Clin. Pharmacol. 2, 197–208 (1975)Google Scholar
  11. Maxwell, C.: Sensitivity and accuracy of the visual analogue scales: A psycho-physical classroom experiment. Br. J. Clin. Pharmacol. 6, 15–24 (1978)Google Scholar
  12. Mellinger, T. J.: Serum concentrations of thioridazine after different oral medication forms. Am. J. Psychiatry 121, 1119–1122 (1965)Google Scholar
  13. Møller-Nielsen, I., Pedersen, V., Nymark, M., Franck, K. F., Boeck, V., Fjalland, B., Christensen, A. V.: The comparative pharmacology of flupenthixol and some reference neuroleptics. Acta Pharmacol. Toxicol. 33, 353–362 (1973)Google Scholar
  14. Nickerson, M., Collier, B.: Drugs inhibiting adrenergic nerves and structures innervated by them. In: The pharmacological basis of therapeutics, L. S. Goodman, A. Gilman, eds., pp. 533–564. New York: Macmillan 1975Google Scholar
  15. Norris, H.: The action of sedatives on brain-stem oculomotor systems in man. Neuropharmacology 10, 181–191 (1971)Google Scholar
  16. Peck, R. E.: The SHP test: An aid in the detection and measurement of depression. Arch. Gen. Psychiatry 1, 35–40 (1959)Google Scholar
  17. Sneddon, J. M., Turner, P.: The interactions of local guanethidine and sympathomimetic amines in the human eye. Arch. Ophthalmol. 81, 622–627 (1969)Google Scholar
  18. Szabadi, E., Bradshaw, C. M.: Speech in affective disorders. In: Psycholinguistics in clinical practice, M. Simpson, ed. New York, Irvington, in press, 1980Google Scholar
  19. Szabadi, E., Bradshaw, C. M., Besson, J. A. O.: Elongation of pausetime in speech: A simple, objective measure of motor retardation in depression. Br. J. Psychiatry 129, 592–597 (1976)Google Scholar
  20. Tyrer, P.: The role of bodily feelings in anxiety. Maudsley Monographs, No. 23. Oxford: Oxford University Press 1976Google Scholar
  21. Wechsler, D.: Manual for the Wechsler adult intelligence scale. New York: Psychological Corporation 1955Google Scholar

Copyright information

© Springer-Verlag 1980

Authors and Affiliations

  • E. Szabadi
    • 1
  • C. M. Bradshaw
    • 1
  • P. Gaszner
    • 1
  1. 1.Department of PsychiatryUniversity of ManchesterManchesterUK

Personalised recommendations